Accord BioPharma is expanding access to short-acting cancer biosimilars with the U.S. commercial launch of FILKRI, a treatment that helps restore neutrophil levels in patients experiencing reduced white blood cell counts. As a biosimilar to Neupogen, FILKRI provides an additional option for managing infection risks associated with chemotherapy and certain other medical conditions.
Approved by the FDA in January 2026, FILKRI is available in two prefilled syringe strengths. The medication joins Accord's existing long-acting UDENYCA treatment, allowing physicians to select between different dosing approaches. Its permanent Medicare and Medicaid billing code became effective October 1, simplifying reimbursement procedures.
For healthcare providers, the expanded portfolio offers greater flexibility in supportive cancer care. Accord also provides benefits verification and co-pay assistance through AccordCares, supporting patient access while strengthening its presence in the competitive U.S. biosimilar market.
Image Credit: Accord BioPharma
Key Themes Behind This Trend
- Short-acting Biosimilars
- Short-acting biosimilar launches are reshaping cancer supportive care by giving clinicians more dosing flexibility and creating room for differentiated access, pricing, and administration models.
- Reimbursement-ready Therapeutics
- Permanent billing codes are becoming a competitive advantage for specialty drugs as simplified reimbursement pathways reduce friction for providers and patients.
- Portfolio-based Oncology Support
- Combined short-acting and long-acting supportive care options highlight a shift toward broader oncology portfolios that can serve varied clinical needs within a single supplier relationship.
Where This Applies
- Biopharmaceuticals
- Biosimilar competition is expanding the biopharmaceutical market by pressuring incumbent biologics while opening space for cost-conscious branded alternatives.
- Oncology Care
- Supportive therapies for chemotherapy-related complications are advancing oncology care by improving treatment continuity and reducing infection-related disruption.
- Healthcare Reimbursement
- Coverage support programs and standardized billing infrastructure are elevating healthcare reimbursement as a key arena for improving specialty drug adoption.
